Lavrov says Russia-Belarus relations developing in working modeRussian Politics & Diplomacy February 21, 21:48
Condolence book in memory of Churkin opened at Russia’s Permanent Mission to UNWorld February 21, 20:53
Ukrainian billionaire Dmitry Firtash detained in Vienna at Spain’s requestWorld February 21, 20:40
UN secretary-general offers Lavrov condolences on Churkin’s deathWorld February 21, 19:53
OPEC does not see problems regarding growth of Russian oil exportBusiness & Economy February 21, 19:46
Kremlin to bake 100,000 pancakes for MaslenitsaSociety & Culture February 21, 19:23
Production of Mercedes Benz cars to start in Russia in 2019Business & Economy February 21, 18:43
UN Security Council holds a minute of silence in memory of Russia’s deceased envoyWorld February 21, 18:30
Russia and US might launch joint operations against terrorists in Raqqa — ministerWorld February 21, 18:17
KHIMKI, September 6. (ITAR-TASS) – Russian scientists are currently working on the first ever vaccine which could help quit smoking; it may be available in pharmacies in as early as five years. Dmitry Ovchinnikov, Deputy Director General of the company developing the drug, Selecta RUS confirmed: “We’re currently going through the second phase of clinical trials.”
Selecta RUS is a subsidiary of an American innovation company which opened the Khimki branch in 2012. Ovchinnikov said that development of the ‘anti-tobacco’ and other vaccines was moved from the U.S. to Russia, as “experts of required qualification work here.” Favorable financing conditions were also a factor: for instance, the vaccine project has received a grant from Russia’s Ministry of Industry and Trade.
The scientists noted that “existing methods of curing tobacco addiction are ineffective,” adding that the new vaccine will be a breakthrough. The drug makes recipient’s body start producing antibodies which block nicotine before it reaches the brain.
Khimki lab scientists are working on a molecular “nano-container,” which can precisely deliver vaccine components in cells which are responsible for launching immune reaction. Produced anti-bodies bind nicotine contained in blood; the resulting complex becomes too large to bypass the blood–brain barrier, which restrict diffusion of dangerous microscopic objects, such as bacteria and harmful molecules. As a result, nicotine cannot access the brain’s “pleasure center” – thus smoking ceases to bring the feeling of euphoria and satisfaction. The chain of pathological tobacco addiction is thus broken.
Ovchinnikov added that Selecta RUS scientists are also working on other vaccines against other afflictions such as melanoma, type 1 diabetes and hepatitis B.
“Operation of this laboratory is a vivid example of technology transfer to Russia,” said Sergei Filippov, representative of Rusnano. He added that Rusnano owns 12% of SelectaBiosciences, the American company which owns Selecta RUS.